Imbria Pharmaceuticals
PrivateLast Round
Series B
Nov 17, 2025
Est. Valuation
$189.2M
Total Funding Raised
$281.1M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Imbria Pharmaceuticals is a biotechnology company that develops innovative therapies aimed at restoring cellular energy production in patients with cardiometabolic disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Imbria Pharmaceuticals Comps
Public and private peers based on sector, stage, and business model.
| Company | Status | Est. Valuation | Rev Multiple |
|---|---|---|---|
| OpenAI | Private | $86.0B | ~40x |
| Cohere | Private | $5.0B | -- |
| Competitor 1 | Public | $XX.XB | XXx |
| Competitor 2 | Public | $XX.XB | XXx |
Imbria Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Nov 17, 2025 | ||||
| Series B | Apr 10, 2025 | ||||
| Series A | Jul 2, 2020 | ||||
| Seed | Jul 9, 2018 |
Key People
Founding team and executive leadership
Imbria Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series B, Seed, Series A |
| SV Health Investors | Series B, Seed, Series A |
| AXA IM Alts | Series B |
| Deep Track Capital | Series B |
| Catalio Capital Management | Series B |
| AN Venture Partners | Series B |
| BNP Paribas Asset Management | Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 17, 2025
$124M round led by Deep Track Capital.
- Oct 16, 2025
Partnered with the Hypertrophic Cardiomyopathy Association (HCMA).
Imbria Pharmaceuticals Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Imbria Pharmaceuticals's valuation, stock price, and market status.